Hot Stock Minute

Caesars big loss; Intercept Pharma soars on positive drug data; Exact Sciences jumps

Here is a look at some of the stocks the Yahoo Finance team will be watching for you today.

Intercept Pharmaceuticals (ICPT) shares soared in early trading after the company said new data revealed that its experimental fatty liver drug treatment is effective and has less-harmful side effects in patients’ cholesterol levels than initially thought. Intercept plans to begin late-stage trials of the treatment in the first half of next year.

Exact Sciences (EXAS) shares rose before the bell. The Food and Drug Administration approved the company's colorectal cancer DNA screening test. Cologuard is the first noninvasive test that patients can use at home.

Caesars Entertainment (CZR) reported a wider-than-expected loss in the second quarter. Revenue also missed estimates, but rose 3% from a year ago. Strong results in Las Vegas were offset by weakness in Atlantic City and other regional markets. Caesars hasn't posted a profit since late 2009 as it struggles with a heavy debt load.

Nuance Communications (NUAN) shares fell in early trading. The speech recognition software maker said it expects earnings and revenue in the current quarter to fall short of analysts' estimates as the company's transition to a subscription-based business model continues to face challenges. Nuance also reported earnings that came right in line with analysts' estimates, but revenue fell short of expectations.

Chiquita Brands (CQB) is also on investors’ watch list this morning. The banana company received an unsolicited joint-offer from two groups with roots in Brazil. The Cutrale Group, an orange juice supplier, and the Safra Group, a private bank, made an offer of $611 million or $13 a share for Chiquita. The banana company is already in the middle of a merger with Irish fruit company Fyffes. That deal, announced in March, would be an inversion where the new company would domicile itself in Ireland for tax purposes.

View Comments (0)